Sign In
Buy GNPX
$0.720
-0.0153 (-2.08%)
At Close: Jun 03, 2026
Genprex to Participate at BIO 2025 International Convention
07:00am, Tuesday, 03'rd Jun 2025
AUSTIN, Texas , June 3, 2025 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patient
Presentation to Highlight Genprex's Study of Reqorsa® Gene Therapy in Combination with Tecentriq® for the Treatment of Extensive Stage Small Cell Lung Cancer AUSTIN, Texas , May 29, 2025 /PRNewswire
Genprex Collaborators Present Positive Preclinical Data on Diabetes Gene Therapy at the ASGCT 28th Annual Meeting
07:00am, Wednesday, 28'th May 2025
Novel Gene Therapy is Addressing Both Type 1 and Type 2 Diabetes AUSTIN, Texas , May 28, 2025 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX ), a clinical-stage gene therapy
Genprex Signs Sponsored Research Agreement with the University of Pittsburgh to Study Diabetes Gene Therapy in Type 1 and Type 2 Diabetes
07:00am, Wednesday, 07'th May 2025
Advances Relationship and Collaboration with the University of Pittsburgh of the Commonwealth System of Higher Education AUSTIN, Texas , May 7, 2025 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "C
Genprex Signs Exclusive License to Additional Gene Therapy Technology with UTHealth Houston for the Treatment of Glioblastoma
07:00am, Tuesday, 06'th May 2025
License Expands Genprex's Portfolio of Oncology Gene Therapy Technologies AUSTIN, Texas , May 6, 2025 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene
Both REQORSA Alone and in Combination with LUMAKRAS® Demonstrated Robust Anti-Tumor Effects in Ras Inhibitor Resistant Non-Small Cell Lung Cancer AUSTIN, Texas , April 30, 2025 /PRNewswire/ -- Genpre
Genprex Collaborators to Present Positive Preclinical Data on Diabetes Gene Therapy at the ASGCT 28th Annual Meeting
07:30am, Tuesday, 29'th Apr 2025
Novel Gene Therapy Program Offers a Promising Opportunity for Curative Therapy in Diabetes AUSTIN, Texas , April 29, 2025 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a c
Genprex Signs Exclusive Technology License Agreement with New York University Langone Health for the Treatment of Mesothelioma
07:30am, Monday, 28'th Apr 2025
Additional Gene Therapy Technology Expands Genprex's Portfolio of Oncology Licenses AUSTIN, Texas , April 28, 2025 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX ), a clinica
Presentation to Highlight Genprex's Study of Reqorsa Gene Therapy in Combination with Tecentriq® for the Treatment of Extensive Stage Small Cell Lung Cancer AUSTIN, Texas , April 24, 2025 /PRNewswire
Genprex Announces Research Collaborators' Abstract Published in Cancer Research Supplement Proceedings
08:15am, Tuesday, 22'nd Apr 2025
Research Journal Features Genprex Collaborators' Abstract Detailing Positive Preclinical Data on the Use ofReqorsa® Gene Therapy for the Treatment of Lung Cancer AUSTIN, Texas , April 22, 2025 /PRNew
Reqorsa® Immunogene Therapy is a Potential Therapy for Ras Inhibitor Resistant Non-Small Cell Lung Cancer AUSTIN, Texas , March 26, 2025 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NA
Novel Gene Therapy Program is Addressing Type 1 and Type 2 Diabetes AUSTIN, Texas , March 25, 2025 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX ), a clinical-stage gene the
Genprex to Participate at BIO Europe Spring 2025
08:15am, Tuesday, 04'th Mar 2025
AUSTIN, Texas , March 4, 2025 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX ), a clinical-stage gene therapy company focused on developing life-changing therapies for patien
Genprex Advances Diabetes Program with Addition of Research Focused on Non-Viral Delivery System
08:15am, Wednesday, 19'th Feb 2025
Researching Novel Diabetes Gene Therapy Using Potentially Re-Dosable Non-Viral Delivery System Strategic Collaboration with CDMO Partner Positions Genprex as a Thought-Leader in Diabetes Market AUSTIN
Genprex Provides Update on Diabetes Gene Therapy Program
08:15am, Tuesday, 18'th Feb 2025
Signs an Amended & Restated License Agreement for Multiple Technologies for Gene Therapy for Type 1 and Type 2 Diabetes Forms a Wholly-Owned Subsidiary, Convergen Biotech, Inc., to Focus Diabetes Prog
